Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protalix BioTherapeuticsPLX +2.18%54 3-Year EPS without NRI Growth Rate is 36.30% as of Jun. 2026, which is 163% above its 10-year median of 13.80. GuruFocus rates PLX with a GF Score™ of 54/100 and a GF Value™ of $2.20 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,161 Biotechnology companies, Protalix BioTherapeutics ranks better than 74.16% on this metric.
During the past 12 months, Protalix BioTherapeutics's average EPS without NRI Growth Rate was 228.60% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 36.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Protalix BioTherapeutics was 60.60% per year. The lowest was -54.60% per year. And the median was 13.80% per year.
Protalix BioTherapeutics (AMEX:PLX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Protalix BioTherapeutics 3-Year EPS without NRI Growth Rate Related Terms
PLX vs GLSI, DTIL, NERV: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Protalix BioTherapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protalix BioTherapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's 3-Year EPS without NRI Growth Rate falls into.
Protalix BioTherapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 36.30% mean?
Protalix BioTherapeutics (PLX) has a 3-Year EPS without NRI Growth Rate of 36.30% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Protalix BioTherapeutics and its competitors. This is 163% above median its historical median of 13.80. According to the industry distribution chart, Protalix BioTherapeutics ranks #300 out of 1161 companies in the Biotechnology industry, placing it in the top 25.8%.
Is Protalix BioTherapeutics' 3-Year EPS without NRI Growth Rate too high?
Protalix BioTherapeutics' current 3-Year EPS without NRI Growth Rate of 36.30% is 163% above median its 10-year median of 13.80. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Protalix BioTherapeutics' value of 36.30% is 124.1% above this industry median. Based on the distribution chart, Protalix BioTherapeutics ranks #300 out of 1161 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Protalix BioTherapeutics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' 3-Year EPS without NRI Growth Rate compare to GLSI and DTIL?
According to the Biotechnology industry distribution chart, Protalix BioTherapeutics ranks #300 out of 1161 companies for 3-Year EPS without NRI Growth Rate. This puts Protalix BioTherapeutics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Protalix BioTherapeutics' value of 36.30% is 124.1% above this benchmark. While the company's 10-year median is 13.80 vs. the industry median of 16.20, Protalix BioTherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protalix BioTherapeutics's current 3-Year EPS without NRI Growth Rate of 36.30% is 124.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Protalix BioTherapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protalix BioTherapeutics's current 3-Year EPS without NRI Growth Rate is 36.30%, which is 163% above median its own 10-year median of 13.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (PLX) is currently considered Fairly Valued. The stock's GF Value™ is $2.20, compared to a current price of $2.34 — trading 6.4% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 36.30%, which is 163% above median its 10-year median of 13.80 and 124.1% above the Biotechnology industry median of 16.20. Protalix BioTherapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Protalix BioTherapeutics (PLX), the current 3-Year EPS without NRI Growth Rate is 36.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (PLX) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of $2.34 is trading 6.4% above its estimated GF Value™ of $2.20.
GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.
Key valuation signals for PLX:
3-Year EPS without NRI Growth Rate: 36.30% (163% above median its 10-year median of 13.80)
GF Value™: $2.20 vs. price of $2.34 (6.4% above fair value)
Industry Position: 124.1% above the Biotechnology median (#300 of 1161)
No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
54GF Score
Get the complete analysis for PLX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLX has been successfully added to your 
